Advertisement

Tumor Biology

, Volume 33, Issue 4, pp 1125–1132 | Cite as

Quantitative assessment of the associations between CYP1A1 polymorphisms and gastric cancer risk

  • Renyong Guo
  • Xichao Guo
Research Article

Abstract

A great number of studies regarding the association between MspI and Ile462Val polymorphisms in the CYP1A1 gene and gastric cancer have been published. However, the results have been inconsistent. In this study, a meta-analysis was performed to investigate the associations. Published literature from PubMed, ISI Web of Science and other Chinese databases were searched for eligible publications. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using random or fixed effect model. Nine studies (860 cases/2183 controls) for CYP1A1 MspI polymorphism and nine studies (1161 cases/3273 controls) for CYP1A1 Ile462Val polymorphism were included in this meta-analysis. MspI polymorphism was not associated with gastric cancer risk (dominant model, OR = 0.95, 95%CI 0.80–1.14; recessive model, OR = 1.01, 95%CI 0.76–1.35; CC vs. TT, OR = 1.03, 95%CI 0.76–1.41; TC vs. TT, OR = 0.95, 95%CI 0.78–1.15). Similarly, there was no association between Ile462Val polymorphism and gastric cancer risk (dominant model, OR = 0.93, 95%CI 0.79–1.10; recessive model, OR = 1.34, 95%CI 0.90–2.00; GG vs. AA, OR = 1.27, 95%CI 0.84–1.90; AG vs. AA, OR = 0.87, 95%CI 0.71–1.07). In the subgroup analysis, no significant association was found in ever smokers, never smokers, Asians and Caucasians. This meta-analysis suggested that there were no associations between CYP1A1 polymorphisms and gastric cancer.

Keywords

CYP1A1 Genetic polymorphism Meta-analysis Gastric cancer 

Notes

Conflicts of interest

None.

References

  1. 1.
    González CA, Agudo A. Carcinogenesis, prevention and early detection of gastric cancer: where we are and where we should go. Int J Cancer. 2011. doi: 10.1002/ijc.26430.
  2. 2.
    Lin YS, Ueda J, Kikuchi S, Totsuka Y, Wei WQ, Qiao YL, et al. Comparative epidemiology of gastric cancer between Japan and China. World J Gastroenterol. 2011;17:4421–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Krejs GJ. Gastric cancer: epidemiology and risk factors. Dig Dis. 2010;28:600–3.PubMedCrossRefGoogle Scholar
  4. 4.
    Nobili S, Bruno L, Landini I, Napoli C, Bechi P, Tonelli F, et al. Genomic and genetic alterations influence the progression of gastric cancer. World J Gastroenterol. 2011;17:290–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Boccia S, Sayed-Tabatabaei FA, Persiani R, Gianfagna F, Rausei S, Arzani D, et al. Polymorphisms in metabolic genes, their combination and interaction with tobacco smoke and alcohol consumption and risk ofgastric cancer: a case–control study in an Italian population. BMC Cancer. 2007;7:206.PubMedCrossRefGoogle Scholar
  6. 6.
    Guengerich FP, Shimada T. Activation of procarcinogens by human cytochrome P450 enzymes. Mutat Res. 1998;400:201–13.PubMedCrossRefGoogle Scholar
  7. 7.
    Bartsch H, Nair U, Risch A, Rojas M, Wikman H, Alexandrov K. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-relatedcancers. Cancer Epidemiol Biomarkers Prev. 2000;9:3–28.PubMedGoogle Scholar
  8. 8.
    Sivaraman L, Leatham MP, Yee J, Wilkens LR, Le Lau AF, Marchand L. CYP1A1 genetic polymorphisms and in situ colorectal cancer. Cancer Res. 1994;54:3692–5.PubMedGoogle Scholar
  9. 9.
    Wang JJ, Zheng Y, Sun L, Wang L, Yu PB, Li HL, et al. CYP1A1 Ile462Val polymorphism and susceptibility to lung cancer: a meta-analysis based on 32 studies. Eur J Cancer Prev. 2011;20:445–52.PubMedCrossRefGoogle Scholar
  10. 10.
    Zhan P, Wang Q, Qian Q, Wei SZ, Yu LK. CYP1A1 MspI and exon7 gene polymorphisms and lung cancer risk: an updated meta-analysis and review. J Exp Clin Cancer Res. 2011;30:99.PubMedCrossRefGoogle Scholar
  11. 11.
    Zheng Y, Wang JJ, Sun L, Li HL. Association between CYP1A1 polymorphism and colorectal cancer risk: a meta-analysis. Mol Biol Rep. 2011. doi: 10.1007/s11033-011-1126-2.
  12. 12.
    Zhuo W, Wang Y, Zhuo X, Zhu Y, Wang W, Zhu B, et al. CYP1A1 and GSTM1 polymorphisms and oral cancer risk: association studies via evidence-based meta-analyses. Cancer Invest. 2009;27:86–95.PubMedCrossRefGoogle Scholar
  13. 13.
    Varela-Lema L, Taioli E, Ruano-Ravina A, Barros-Dios JM, Anantharaman D, Benhamou S. Meta-analysis and pooled analysis of GSTM1 and CYP1A1 polymorphisms and oral and pharyngeal cancers: a HuGE-GSEC review. Genet Med. 2008;10:369–84.PubMedCrossRefGoogle Scholar
  14. 14.
    Sergentanis TN, Economopoulos KP. Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2010;122:459–69.PubMedCrossRefGoogle Scholar
  15. 15.
    Sergentanis TN, Economopoulos KP, Choussein S, Vlahos NF. Cytochrome P450 1A1 gene polymorphisms and endometrial cancer risk: a meta-analysis. Int J Gynecol Cancer. 2011;21:323–31.PubMedCrossRefGoogle Scholar
  16. 16.
    Shaik AP, Jamil K, Das P. CYP1A1 polymorphisms and risk of prostate cancer: a meta-analysis. Urol J. 2009;6:78–86.PubMedGoogle Scholar
  17. 17.
    González A, Ramírez V, Cuenca P, Sierra R. Polymorphisms in detoxification genes CYP1A1, CYP2E1, GSTT1 and GSTM1 in gastric cancer susceptibility. Rev Biol Trop. 2004;52:591–600.PubMedGoogle Scholar
  18. 18.
    Roth MJ, Abnet CC, Johnson LL, Mark SD, Dong ZW, Taylor PR, et al. Polymorphic variation of Cyp1A1 is associated with the risk of gastric cardia cancer: a prospective case–cohort study of cytochrome P-450 1A1 and GST enzymes. Cancer Causes Control. 2004;15:1077–83.PubMedCrossRefGoogle Scholar
  19. 19.
    Suzuki S, Muroishi Y, Nakanishi I, Oda Y. Relationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancer. J Gastroenterol. 2004;39:220–30.PubMedCrossRefGoogle Scholar
  20. 20.
    Li H, Chen XL, Li HQ. Polymorphism of CYPIA1 and GSTM1 genes associated with susceptibility of gastric cancer in Shandong Province of China. World J Gastroenterol. 2005;11:5757–62.PubMedGoogle Scholar
  21. 21.
    Nan HM, Song YJ, Yun HY, Park JS, Kim H. Effects of dietary intake and genetic factors on hypermethylation of the hMLH1 gene promoter in gastric cancer. World J Gastroenterol. 2005;11:3834–41.PubMedGoogle Scholar
  22. 22.
    Shen J, Wang RT, Xu YC, Wang LW, Wang XR. Interaction models of CYP1A1, GSTM1 polymorphisms and tobacco smoking in intestinal gastric cancer. World J Gastroenterol. 2005;11:6056–60.PubMedGoogle Scholar
  23. 23.
    Agudo A, Sala N, Pera G, Capellá G, Berenguer A, García N, et al. Polymorphisms in metabolic genes related to tobacco smoke and the risk of gastric cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev. 2006;15:2427–34.PubMedCrossRefGoogle Scholar
  24. 24.
    Lee K, Cáceres D, Varela N, Csendes DA, Ríos RH, Quiñones SL. Allelic variants of cytochrome P4501A1 (CYP1A1), glutathione S transferase M1 (GSTM1) polymorphisms and their association with smoking and alcohol consumption as gastric cancer susceptibility biomarkers. Rev Med Chil. 2006;134:1107–15.PubMedGoogle Scholar
  25. 25.
    Ma JX, Zhang KL, Liu X, Ma YL, Pei LN, Zhu YF, et al. Concurrent expression of aryl hydrocarbon receptor and CYP1A1 but not CYP1A1 MspI polymorphism is correlated with gastric cancers raised in Dalian, China. Cancer Lett. 2006;240:253–60.PubMedCrossRefGoogle Scholar
  26. 26.
    Huang X. A case–control study on the association between genetic polymorphisms of CYP1A1, GSTM1 and gastric cancer susceptibility in GuangXi Province. Doctor’s Thesis of Guangxi Medical University. 2007; 1–95.Google Scholar
  27. 27.
    Wideroff L, Vaughan TL, Farin FM, Gammon MD, Risch H, Stanford JL, et al. GST, NAT1, CYP1A1 polymorphisms and risk of esophageal and gastric adenocarcinomas. Cancer Detect Prev. 2007;31:233–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Kobayashi M, Otani T, Iwasaki M, Natsukawa S, Shaura K, Koizumi Y, et al. Association between dietary heterocyclic amine levels, genetic polymorphisms of NAT2, CYP1A1, and CYP1A2 and risk of stomachcancer: a hospital-based case–control study in Japan. Gastric Cancer. 2009;12:198–205.PubMedCrossRefGoogle Scholar
  29. 29.
    Malik MA, Upadhyay R, Mittal RD, Zargar SA, Modi DR, Mittal B. Role of xenobiotic-metabolizing enzyme gene polymorphisms and interactions with environmental factors in susceptibility to gastric cancer in Kashmir Valley. J Gastrointest Cancer. 2009;40:26–32.PubMedCrossRefGoogle Scholar
  30. 30.
    Darazy M, Balbaa M, Mugharbil A, Saeed H, Sidani H, Abdel-Razzak Z. CYP1A1, CYP2E1, and GSTM1 gene polymorphisms and susceptibility to colorectal and gastric cancer among Lebanese. Genet Test Mol Biomarkers. 2011;15:423–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Luo YP, Chen HC, Khan MA, Chen FZ, Wan XX, Tan B, et al. Genetic polymorphisms of metabolic enzymes-CYP1A1, CYP2D6, GSTM1, and GSTT1, and gastric carcinoma susceptibility. Tumour Biol. 2011;32:215–22.PubMedCrossRefGoogle Scholar
  32. 32.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsis-tency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRefGoogle Scholar
  33. 33.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRefGoogle Scholar
  34. 34.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  35. 35.
    Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.PubMedCrossRefGoogle Scholar
  36. 36.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRefGoogle Scholar
  37. 37.
    Spurr NK, Gough AC, Stevenson K, Wolf CR. Msp-1 polymorphism detected with a cDNA probe for the P-450 I family on chromosome 15. Nucleic Acids Res. 1987;15:5901.PubMedCrossRefGoogle Scholar
  38. 38.
    Little J, Sharp L, Masson LF, Brockton NT, Cotton SC, Haites NE, et al. Colorectal cancer and genetic polymorphisms of CYP1A1, GSTM1 and GSTT1: a case–control study in the Grampian region of Scotland. Int J Cancer. 2006;119:2155–64.PubMedCrossRefGoogle Scholar
  39. 39.
    Yeh CC, Sung FC, Tang R, Chang-Chieh CR, Hsieh LL. Association between polymorphisms of biotransformation and DNA-repair genes and risk of colorectal cancer in Taiwan. J Biomed Sci. 2007;14:183–93.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  1. 1.Department of Laboratory Medicine, the First Affiliated Hospital, College of MedicineZhejiang UniversityHangzhouChina

Personalised recommendations